Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer
Status:
Recruiting
Trial end date:
2022-12-07
Target enrollment:
Participant gender:
Summary
This phase Ib/II trial studies how well sorafenib tosylate and pembrolizumab work in treating
patients with liver cancer that has spread to other parts of the body. Sorafenib tosylate may
stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells
to grow and spread. Giving sorafenib tosylate and pembrolizumab may work better in treating
patients with liver cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Roswell Park Cancer Institute
Collaborators:
Merck Sharp & Dohme Corp. National Cancer Institute (NCI)